Ipsen Announces Analysis of Managed Medicaid Data of Children with Cerebral Palsy at Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine 42 Percent of Children with Cerebral Palsy Not Receiving Spasticity Management Therapies, According to Retrospective Study on Medicaid Costs

BASKING RIDGE, N.J., September 15, 2017 – Ipsen Biopharmaceuticals, Inc., an affiliate of
Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced a presentation of data from a
retrospective study on managed Medicaid costs of treating children with Cerebral Palsy (CP) at
the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine
(AACPDM) on September 13-16, 2017 in Montreal, Canada. This data evaluated recent, largescale, landscape studies of the burden of illness for CP patients in the U.S.

Cerebral Palsy is a term for a group of neurological disorders that appear in infancy or early
childhood and affect the part of the brain that controls muscle movements.1 One of the
symptoms associated with CP is spasticity – a condition in which there is an abnormal increase
in muscle tone or stiffness in one or more muscles.2

The study objective was to better understand the epidemiology, treatment patterns, resource
utilization and associated costs of children with CP in the U.S. Managed Medicaid data from a
proprietary database covering 15 states and encompassing seven million lives between 2013-
2015 was analyzed, with 3,294 unique cases, which represent patients with CP (aged 2-20)
identified through ICD-9/10 diagnosis codes.

The analysis indicates that 42 percent of children diagnosed with CP did not receive any of 10
selected therapies commonly used for spasticity management; these therapies included
physical therapy, orthotics, oral baclofen, botulinum toxin, anti-spasm medication, casting,
orthopedic surgery, baclofen injection, baclofen pumps, and rhizotomies. These therapies were
selected by a group of multidisciplinary researchers and care team members who determined
that these methods were the most commonly used spasticity management options for CP

The data also showed the average annual cost of treatment for a child with CP was about 16
times higher than the average cost of treatment for any child enrolled in Medicaid ($22,383
versus $1,359, respectively) between the years 2013 and 2015. Annual costs included
expenditure from utilization of pharmacy, medical services, home health, long term care and
hospice. Because CP disease severity cannot be obtained from diagnosis codes, the study
team developed clinical algorithms to assess the likelihood of ambulation among CP children;
30.5 percent were identified as likely ambulatory, 33.8 percent as likely non-ambulatory, and the
remainder unknown. Children with CP that were likely non-ambulatory had average annual
costs four times higher than those for children with CP who were likely ambulatory. There was
large variability in the medical expenditure for children with CP, even for those with the same
ambulatory status. This may be driven in part by regional Medicaid coverage differences.
Limitations of this retrospective study include incomplete or inaccurate submitted claims. Further
research is needed to understand the specific cost drivers associated with the care of children
with CP.

“This study supports the need for a broader look into the overall management plans for children
living with Cerebral Palsy, including appropriate treatment options and physical and
occupational therapies. We hope this would also lead to better management of costs for
families,” said David Cox, VP North American Medical, HEOR & Regulatory Affairs, Ipsen.
“Ipsen is committed to improving the care of children with lower limb spasticity – especially
those with Cerebral Palsy, the most common motor disability in children.3

About Ipsen in North America
Ipsen Biopharmaceuticals, Inc. is the US affiliate of Ipsen, a global specialty-driven
pharmaceutical group. The US head office is located in Basking Ridge, New Jersey. Ipsen
Biopharmaceuticals Canada, Inc. is an integrated business unit within North America and has its
head office located in Mississauga, Ontario. Ipsen Bioscience, Inc., the Ipsen US research and
development center focused on peptide research in oncology and endocrinology, is located in
Cambridge, Massachusetts. At Ipsen Bioscience, we focus on creating a highly cooperative and
passionate R&D organization through partnerships, innovation, and continuous learning to
effectively deliver new treatments for patients. At Ipsen, we focus our resources, investments,
and energy on discovering, developing, and commercializing new therapeutic options for
oncologic, neurologic, and endocrine diseases. For more information on Ipsen in North America,
please visit www.ipsenus.com or www.ipsen.ca.

About Ipsen
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty
care. The group develops and commercializes innovative medicines in three key therapeutic
areas – Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is
exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine
tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established
Consumer Healthcare business. With total sales close to €1.6 billion in 2016, Ipsen sells more
than 20 drugs in over 115 countries, with a direct commercial presence in more than 30
countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms
located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France;
Oxford, UK; Cambridge, US). The Group has about 5,100 employees worldwide. Ipsen is listed
in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit

Forward Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the
Group’s management strategy, current views and assumptions. Such statements involve known
and unknown risks and uncertainties that may cause actual results, performance or events to
differ materially from those anticipated herein. All of the above risks could affect the Group’s
future ability to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today. Use of the words
“believes,” “anticipates” and “expects” and similar expressions are intended to identify forwardlooking statements, including the Group’s expectations regarding future events, including
regulatory filings and determinations. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions and potential future
acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts
likely to happen in the future, and not exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain risks and uncertainties, notably
the fact that a promising product in early development phase or clinical trial may end up never
being launched on the market or reaching its commercial targets, notably for regulatory or
competition reasons. The Group must face or might face competition from generic products that
might translate into a loss of market share. Furthermore, the Research and Development
process involves several stages each of which involves the substantial risk that the Group may
fail to achieve its objectives and be forced to abandon its efforts with regards to a product in
which it has invested significant sums. Therefore, the Group cannot be certain that favorable
results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or
that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of
the product concerned. There can be no guarantees a product will receive the necessary
regulatory approvals or that the product will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements. Other risks and uncertainties
include but are not limited to, general industry conditions and competition; general economic
factors, including interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation; global trends toward health care
cost containment; technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory approval; the
Group’s ability to accurately predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and sovereign risk; dependence on the
effectiveness of the Group’s patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory actions. The Group also
depends on third parties to develop and market some of its products which could potentially
generate substantial royalties; these partners could behave in such ways which could cause
damage to the Group’s activities and financial results. The Group cannot be certain that its
partners will fulfill their obligations. It might be unable to obtain any benefit from those
agreements. A default by any of the Group’s partners could generate lower revenues than
expected. Such situations could have a negative impact on the Group’s business, financial
position or performance. The Group expressly disclaims any obligation or undertaking to update
or revise any forward looking statements, targets or estimates contained in this press release to
reflect any change in events, conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. The Group’s business is subject to
the risk factors outlined in its registration documents filed with the French Autorité des Marchés

For further information:
Marisol Peron 
Vice President, North American
Internal & External Communications
Tel: 908-275-6330
E-mail: marisol.peron@ipsen.com

Katie Zied
Tel: 646-722-8807
E-mail: kzied@centronpr.com

1. National Institute of Neurological Disorders and Stroke. NINDS Cerebral Palsy
Information Page. https://www.ninds.nih.gov/Disorders/All-Disorders/Cerebral-PalsyInformation-Page. Accessed September 12, 2017
2. National Institute of Neurological Disorders and Stroke. Spasticity Information Page.
Accessed September 12, 2017.
3. Centers for Disease Control and Prevention: Data & Statistics for Cerebral Palsy.
http://www.cdc.gov/ncbddd/cp/data.html. Accessed May 2, 2016.

# # #
© 2017 Ipsen Biopharmaceuticals, Inc.
September 2017 DYS-US-002203

©2020 Ipsen Biopharmaceuticals, Inc. All rights reserved. June 2020 CR-CA-000013